Table 1.

Baseline characteristics of participants with autosomal dominant polycystic kidney disease enrolled in the TEMPO 3:4 and REPRISE trials

CharacteristicTEMPO 3:4REPRISE
Tolvaptan (n=961)Placebo (n=484)Tolvaptan (n=683)Placebo (n=687)
Age, yr39±739±747±847±8
Male sex, no. (%)495 (52)251 (52)347 (51)333 (48)
Height, cm174±10174±8174±10173±10
Weight, kg79±1879±1885±2082±19
Race, no. (%)
 White810 (84)408 (84)626 (92)632 (92)
 Asian121 (13)62 (13)22 (3)19 (3)
 Other30 (3)14 (3)35 (5)36 (5)
eGFR, ml/min per 1.73 m281±2182±2341±1141±11
eGFR category, ml/min per 1.73 m2, no. (%)
 ≥90330 (34)172 (36)00
 60–89465 (48)224 (46)32 (5)a39 (6)a
 45–59135 (14)70 (14)209 (31)202 (29)
 30–4428 (3)15 (3)303 (44)315 (46)
 15–2900139 (20)128 (19)
  • Values are mean±SD or n (%). TEMPO 3:4, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 trial; REPRISE, Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD trial.aPer eligibility criteria for REPRISE, subjects in this eGFR category were in the range 60–65 ml/min per 1.73 m2.